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          INTRODUCTION
 Oral solid dosage form1,2:
The oral route of drug administration is the most important method of administering
drug for systemic effects. Except in certain case the parental route is not routinely used for
self administration, e.g. insulin. The topical route of administration has only recently been
employed  to  deliver  drugs  to  the  body  for  systemic  effect.  The  parental  route  of
administration is important in treating medical emergencies in which the subject is comatose
or cannot swallow. Nevertheless it is probable that at least 90% of all drugs used to provide
systemic effect are administered by oral route. When a new drug is discovered one of the
first question a pharmaceutical company asks is whether or not the drug can be effectively
administered for its intended effect by oral route.  Drugs that are administered orally, solid
oral dosage forms represent the preferred class of product. Tablet and capsules represent unit
dosage forms in which usual dose of drug has been accurately placed.
Tablets  and  capsules  represent  unit  dosage  forms  in  which  one  usual  dose  of
drug has been accurately placed. By comparison liquid forms such as syrups, suspensions,
emulsions, solutions and elixirs are usually designated to contain one medication in 5 -30ml,
such dosage measurements are typically error by a factor ranging from 20 -50%, when the
drug is self administered by patient.
Tablets3,4:
 In 1843, the first patent for a hand operated device used to form a tablet was granted. Tablets
are  defined  as  solid  dosage  forms  each  containing  a  single  dose  of  one  or  more  active
ingredients, obtained by compressing uniform volumes of particles. They are intended for the
oral  administration,  some  are  swallowed  whole,  some  after  being  chewed.  Some  are
dissolved or dispersed in aqueous phase before being administered and some are retained in
the mouth, when the active ingredients are “liberated”.
Tablets are used mainly for systemic drug delivery but also for local drug action. For
systemic  use drug  must  be released  from tablet  that  is  dissolved  in  the  fluids  of  mouth,
stomach and intestine and then absorbed into systemic circulation by which it reaches its site
of action.
The tablet is composed of the Active Pharmaceutical Ingredient (active drug) together with
various  excipients.  These  are  biologically  inert  ingredients  which  either  enhance  the
1
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therapeutic effect or are necessary to construct the tablet. The filler or diluents (e.g. Lactose
or Sorbitol) are a bulking agent, providing a quantity of material which can accurately be
formed into a tablet. Binders (e.g. methyl cellulose or gelatin) hold the ingredients together so
that they can form a tablet. Lubricants (e.g. magnesium stearate or polyethylene glycol) are
added to reduce the friction between the tablet and the punches and dies so that the tablet
compression and ejection processes are smooth. Disintegrants (e.g. starch or cellulose) are
used to promote wetting and swelling of the tablet so that it breaks up in the gastrointestinal
tract; this is necessary to ensure dissolution of the API.  Superdisintegrants are sometimes
used to greatly speed up the disintegration of the tablet. Additional ingredients may also be
added  such  as  coloring  agents,  flavoring  agents  and  coating  agents.  Formulations  are
designed  using  small  quantities  in  a  laboratory  machine  called  a  Powder  Compaction
Simulator. This can prove the manufacturing process and provide information.   
Advantages1:
• They are unit dosage forms and they offer the greatest capabilities of all oral dosage
forms for the greatest dose precision and the least content variability. 
• Their cost is lowest of all oral dosage forms. 
• They are the lightest and most compact oral dosage forms. 
• They are in general the easiest and cheapest to package. 
• Product  identification  is  potentially  the  simplest  and  cheapest,  requiring  no
additional processing steps when employing an embossed or monogrammed punch face. 
• They may provide the greatest ease of swallowing with the least tendency for “hang-
up” above  the  stomach especially  when coated  provided  the  tablet  disintegration  is  not
excessively rapid. 
• They lend themselves to certain special release profile products such as enteric or
delayed release products. 
• They are better suited to large scale production than other unit oral forms. 
 Disadvantages:
• Some  drugs  resist  compression  into  dense  compacts,  owing  to  their  amorphous
nature or flocculent, low density character. 
2
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• Drugs  with  poor  wetting,  dissolution  properties,  intermediate  to  large  dosages,
optimum absorption high in the GIT or any combination of these features may be difficult to
impossible to formulate and manufacture as a tablet that will still provide adequate full drug
bioavailability. 
• Bitter tasting drugs, drugs with an objectionable odour or drugs that are sensitive to
oxygen  or  atmospheric  moisture  may  require  encapsulation  or  entrapment  prior  to
compression or the tablets may require coating. In such cases, the tablets may offer the best
and lowest cost approach.
  Types of tablets1:
      The main reason behind formulation of different types of tablets are to create a delivery
system that is relatively simple and inexpensive to manufacture, provide the dosage form
that is convenient from patients perspective and utilize an approach that is unlikely to add
complexity during regulatory approval process. To perceive each dosage form, tablets here
are classified by their route of administration and by the type of drug the delivery system
represent within that route.
Oral tablets for ingestion:
 Standard compressed tablets
 Multiple compressed tablets
• Compression coated tablets 
• Layered tablets 
• Inlay tablets 
 Modified release tablets
 Delayed action tablets
 Targeted action tablets
• Floating tablets
• Colon targeting tablets
3
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 Chewable tablets
 Dispersible tablets
 Tablets used in the oral cavity
 Lozenges and troches
 Sublingual tablets
 Buccal tablets
 Dental cones
 Mouth dissolving tablets
     Tablets administered by other routes:
 Vaginal tablets
 Implants
    Tablets used for prepare solution:
 Effervescent tablets
 Hypodermic tablets
 Soluble tablets
METHODS INVOLVED IN FORMULATION OF TABLETS5:
 Direct compression 
 Dry granulation 
 Wet granulation 
 Direct compression: 
This method is used when a  group of ingredients can be blended and placed in a tablet press
to make a  tablet  without any of  the ingredients  having to  be changed.  This  is  not  very
frequent because many tablets have active pharmaceutical ingredients which will not allow
4
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for the direct compression due to their concentration or the excipients used in formulation
are not conducive to direct compression.
 Granulation is the process of collecting the particles together by creating bonds between
them. There are several different methods of granulation. The most popular, which is used
by over 70% of formulation in tablet manufacture is wet granulation.
Advantages of Direct Compression:
1. Cost Effectiveness
2. Stability. 
3. Faster Dissolution
4. Less wears & tears of punches
5. Simplified Validation
Limitations of direct compression
1. Segregation
2. Cost 
3. Low dilution potential
4. Re-workability
5. Lubricant sensitivity
6. Variation in functionality 
Dry granulation:
In dry granulation process the powder mixture is compressed without the use of heat and
solvent. It is the least desirable of all methods of granulation. The two basic procedures are
to  form a  compact  of  material  by compression  and  then  to  mill  the  compact  to  obtain
granules.  Two methods  are  used  for  dry  granulation.  The more  widely  used  method is
slugging, where the powder is recompressed and the resulting tablet or slug are milled to
yield the granules. The other method is to precompress the powder with pressure rolls using
a machine such as Chilsonator.
Roller compaction
The compaction of powder by means of pressure roll can also be accomplished by a machine
called chilsonator. Unlike tablet machine, the chilsonator turns out a compacted mass in a
steady continuous flow. The powder is fed down between the rollers from the hopper which
5
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contains  a  spiral  auger  to  feed  the  powder  into  the  compaction  zone.  Like  slugs,  the
aggregates are screened or milled for production into granules.
 Use: Use in the production of directly compressible excipients, the compaction of drugs and
drug  formulations,  the  granulation  of  inorganic  materials,  the  granulation  of  dry  herbal
material and the production of immediate/sustained release formulations.
Processing steps:
     Weighing of raw material, screening, mixing, and compression to slugs-milling-mixing-
compression to finished tablets.
Advantages:
The main advantage of dry granulation or slugging is  that it uses less equipments and space.
It eliminate the need for binder solution, heavy mixing equipment and the costly and time
consuming drying step required for wet granulation. Slugging can be used for advantages in
the following situations:
i) For moisture sensitive material.
ii) For heat sensitive material.
iii) For improved disintegration since powder particles are not bonded together by a       
binder.
Disadvantages:
i)  It requires a specialized heavy duty tablet press to form slug.
ii)  It does not permit uniform colour distribution as can be achieved with wet granulation
where the dye can be incorporated into binder liquid.
iii) The process tends to create more dust than wet granulation, increasing the potential for
contamination.
Wet granulation: 
      The most broadly used process  of agglomeration in pharmaceutical industry is  wet
granulation. Wet granulation process simply involves the wet massing of the powder blend
with a granulating liquid, wet sizing and drying.
Important steps involved in the wet granulation:
i) Mixing of the drug(s) and excipients.
ii) Preparation of binder solution.
6
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iii) Mixing of binder solution with powder mixture to form wet mass. 
iv) Drying of moist granules.
v) Mixing of screened granules with disintegrant, glidant, and lubricant.
Advantages
(a) Permits mechanical handling of powders without loss of mix quality.
(b) Improves the flow of powders by increasing particle size and sphericity.
(c) Increases and improves the uniformity of powder density.
(d) Improves cohesion during and after compaction.
(e) Reduces air entrapment.
(f) Reduces the level of dust and cross-contamination.
(g) Allows for the addition of a liquid phase to powders (wet process only).
(h) Makes hydrophobic surfaces hydrophilic.
Limitation of wet granulation:
i) The greatest disadvantage of wet granulation is its cost. It is an expensive process because
of labor, time, equipment, energy and space requirements.
ii) Loss of material during various stages of processing.
iii) Stability may be major concern for moisture sensitive or thermolabile drugs.
iv) Multiple processing steps add complexity and make validation and control difficult.
v) An inherent limitation of wet granulation is that any incompatibility between formulation
components is aggravated.
 Chewable tablets1:
                Chewable tablets are intended to be chewed in the mouth prior to swallowing and
are not intended to be swallowed intact. The purpose of the chewable tablet is to provide
unit dosage form of medication which can be easily administered to infants and children or
to the elderly, who may have difficulty in swallowing a tablet intact. 
Chewable dosage forms, such as soft pills, tablets, gums and most recently chewy squares
have long been part of the pharmacist armamentarium.
 Advantages6:
 Better bioavailability through bypassing disintegration.
 Patient convenience through the elimination of the need for water for swallowing.
 Possible use as a substitute for liquid dosage forms where rapid onset of action is   
            needed.                                                                                           
 Improve patient acceptance (especially in pediatrics).
 Better stability.
7
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 Techniques used in the formulation of chewable tablets6:
 Coating by wet granulation
 Microencapsulation
 Solid dispersion
 Adsorbate formation technique
 Ion exchange
 Spray congealing and spray coating
 Formation of different salts or derivatives 
 Use of amino acids and protein hydrolysates
 Inclusion complexes 
 Molecular complexes
COATING BY WET GRANULATION:
       This process may be described as one which agglomerates drug particles through a
combination of adhesion and cohesion using a wetting agent and binder.  This process is
primarily intended to impart flow ability and compressibility to imputable substances, under
certain conditions it may be useful in the application of coatings to drug particles in order to
mask or reduce the bitter taste .Taste improvement  by coating is attractive in its simplicity,
this method only suffix for mildly to moderately and pleasant tasting drugs .
MICROENCAPSULATION:
Microencapsulation  is  a  method of  coating  drug  particles  or  liquid  droplets  with  edible
polymeric  materials  there  by  masking  the  taste  and  forming  relatively  free  flowing
microcapsules of 5 to 5000µm.This process essentially consists of three steps 
1. Formation of three immiscible phases. 
2.  Depositing  the  liquid  polymer  coating  by  sorption  around  the  core  material  under
controlled physical mixing of the three phases.
3. Rigidizing the coating, by thermal cross linking or desolvation techniques, to form a rigid
microcapsule.
The resultant coated granules not only mask the taste of the drug but also minimize any
physical and chemical incompatibility between ingredients.
SOLID DISPERSION:
8
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Bad  tasting drugs  can  be prevented  from stimulating  the taste  buds  by adsorption onto
substrates capable of keeping the drugs adsorbed while in the mouth but releasing them
eventually in the stomach or gastrointestinal tract. The adsorbent is commercially available
in the form of micronized powder with the drug content of 10% w/w.
ADSORBATE FORMATION TECHNIQUE:
Solvent method
The formation of an adsorbate involves the drug in a solvent, mixing the solution with the
substrate  and  evaporating  the  solvent  leaving  the  drug  molecules  adsorbed  up  on  the
substrate.
Melting method
The drug or drugs and a carrier are melted together by heating the melted mixture. It is then
cooled  and  rapidly  solidified  in  a  ice  bath  with  vigorous  stirring  .The  product  is  then
pulverized and sized.
ION EXCHANGE:
The reversible interchange of ions between a solid and a liquid phase in which there is no
permanent change in the structure of solid .The solid is the ion exchanger material while the
ion could be a drug ion exchange materials provide a means for binding drugs on to an
insoluble polymeric matrix and can effectively mask the problems of taste and odour, in
drugs to be formulated in to chewable tablets.
SPRAY CONGEALING AND SPRAY COATING:
The process of spray congealing involves cooling of melted substances in the form of fine
particles during their travel in a spray nozzle to the distant vicinity of a spray chamber held
at a temperature below their melting point .The application is best exemplified by the taste
masking of the thiamine mononitrate, riboflavin, pyridoxine hydrochloride and niacinamide
by fatty acids.
FORMATION OF DIFFERENT SALTS OR DERIVATIVES:
9
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 This approach is to modify the chemical composition of the drug substance itself , so as to
render it less soluble in saliva and thereby less stimulating for the taste buds , or to obtain a
tasteless or less bitter form. 
USE OF AMINO ACIDS AND PROTEIN HYDROLYSATES:
By combining amino acids, their salts, or a mixture of two, it is possible to substantially
reduce the bitter taste of penicillin. Some of the preferred amino acids are sarcosine, alanine,
glycine, glutamic acid.
INCLUSION COMPLEXES
 In inclusion complex formation, the drug molecule (guest molecule) fits into the cavity of a
complexing agent (host molecule)  forming a stable complex. The complex is capable of
masking the bitter taste of the drug by both decreasing the amount of drug particles exposed
to the taste buds and decreasing the drug solubility on ingestion.
 MOLECULAR COMPLEXES:
It involves a drug and a complexing organic molecule and, like inclusion complexes, can be
used in the masking of the bitter taste or odour of drugs by forming complexes.  
 Role of disintegrants in the manufacturing of chewable tablets7:
Disintegrants are substances commonly included in tablet formulations and in some hard
shell capsule preparations to benefit penetration and dispersion of the matrix of the dosage
form in dissolution fluids. An oral solid dosage form should admirably disperse into the
primary particles from which it was prepared.  Disintegrants are the agents added to tablet
(and some encapsulated)  formulations to promote the breakup of the tablet  (and capsule
“slugs’) into smaller fragments in an aqueous environment thereby increasing the available
surface area and promoting a more rapid release of the drug substance.
 Mechanism of disintegrants: 
 There are four major mechanisms for tablets disintegration as follows
 Swelling:
10
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The  most  widely  recognised  general  mechanism  of  action  for  tablet  disintegration  is
swelling.  Tablets  with  high  porosity  and  lack  of  adequate  swelling  force  show  poor
disintegration. On the other hand, tablet with low porosity exert sufficient swelling force. It
is worthy to note that if the packing fraction is very high, fluid is unable to penetrate in the
tablet and disintegration slows down.
 Porosity and capillary action(Wicking):
Disintegration by capillary action is always the first step. When we add the tablet into a
suitable  aqueous  medium,  the  medium  penetrates  into  the  tablet  and  replaces  the  air
absorbed on the particles, which weakens the intermolecular bond and breaks the tablet into
fine particles. Water uptake by tablet banks on hydrophilicity of the drug/excipient and on
tabletting conditions. For these types of disintegrants sustainance of porous structure and
low interfacial tension towards water is mandatory which helps in disintegration by creating
a hydrophilic network around the drug particles.
                Fig No 1:  Mechanism of disintegrants by swelling and wicking 
 Due to disintegrating particles repulsive forces:
Another mechanism of disintegration attempts to elucidate the swelling of tablet made with
‘nonswellable’ disintegrants. Guyot-Hermann has adduced a particle repulsion theory based
11
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on the observation that nonswelling particle also cause disintegration of tablets. The electric
repulsive forces between particles make the basis for disintegration and water is required for
it. Researchers found that repulsion is secondary to wicking. 
                       Fig No 2:  Mechanism of disintegrants by deformation and repulsion 
 Due to deformation:
During  tablet  compression,  disintegrating  particles  get  deformed  and  these  deformed
particles get into their normal structure when they come in contact with aqueous media or
water.  Occasionally  the  swelling  capacity  of  starch  was  increased  when  granules  were
extensively deformed during compression. This increase in size of the deformed particles
produces a breakup of the tablet.
  Method of addition of disintegrants8:
  The ideal disintegrant should have the following characteristics:
 Poor solubility
 Poor gel formation
 Good hydration capacity 
 Good molding and flow properties 
 No tendency to form complexes with the drugs
Disintegrants are essentially added to tablet granulation for making the compressed tablet to
break or disintegrate  when placed in aqueous environment.  Disintegrating agents  can be
added to tablets by two methods:
 Internal addition(Intragranular)
12
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 External addition (Extra granular)
 Partly Internal and External
 
In extragranular method, the disintegrant is added to the sized granules with mixing prior to
compression. In intragranular method, the disintegrant is mixed with other powders before
wetting the powder mixtures with the granulating fluid. Thus the disintegrant is incorporated
within the granules. When these methods are employed, part of disintegrant can be added
internally and part externally.  This technique provides immediate disruption of the tablet
into  previously  compressed  granules  while  the  disintegrating  agent  within  the  granules
causes further erosion of the granules to the original powder particles. This two step method
usually produces better and complete disintegration than the regular method of adding the
disintegrant to the granulation surface only.
            
Factors effecting action of disintegrants:
 Percentage of disintegrants present in the tablets
 Types of substances present in the tablets
 Combination of disintegrants
 Presence of surfactants
 Hardness of the tablets.
 Nature of drug substances
 Mixing and screening
Because  of  the  increased  demands  for  improved  dissolution  requirements,  there  are
currently,  a  new  generation  of  “Superdisintegrants”.  These  novel  substances  are  more
effective at lower concentrations with greater disintegrants swell, hydrate, change volume or
form and produce a disruptive change in the tablet. Effective superdisintegrants facilitate
improved  compressibility,  compatibility and have no negative  impact  on the mechanical
strength  of  formulations  containing  high-dose  drugs.  They  are  widely  used  in  wet
granulation and direct compression applications.
                                Table No 1: Classification of superdisintegrants9
Structural  type  (NF
name)
Description Trade  name
(manufacturer)
Modified  starches
(sodium  starch  glycolate,
NF)
Sodium  carboxymethyl
starch;  the  carboxymethyl
groups  induces
Explotab®  (Edward
Mendell Co.), Primojel®
(Generichem  Corp.),
13
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hydrophilicity  and  cross
linking reduces solubility
Tablo®  (Blanver,
Brazil)
Modified  cellulose
(Croscarmellose,NF)
Sodium  carboxy  methyl
cellulose  which  has  been
cross-linked  to  render  the
material insoluble.
AcDiSol® (FMC Corp.),
Nymcel  ZSX®  (Nyma,
Nertherlands),
Primellose®  (Avebe,
Netherlands)  Solutab®
(Blanver,Brazil)
Cross-linked  poly-
vinylpyrrolidone
(Crospovidone,NF)
Cross-linked
polyvinylpyrrolidone;  the
high molecular weight and
cross-linking  render  the
material  insoluble  in
water.
Crospovidone  M®
(BASF Corp.),  Kollidon
CL®  (BASE  Corp.),
Polyplasdone  XL  (ISP
Corp.)
Three major types  of compounds have been developed which swell  to many times their
original size when placed in water while providing minimal viscosity effects.
1. Modified starches – Sodium Carboxymethyl (Chemically treated Potato Starch) starch
i.e. Sodium Glycolate (Explotab, Primogel)
Mechanism of action: Rapid and extensive swelling with minimum gelling.
Effective Concentration: 4-6%. Above 8% disintegration times may actually increase due
to gelling and its subsequent viscosity providing effects.
2.  Cross-linked  polyvinylpyrrolidone -  water  insoluble  and  strongly  hydrophilic  i.e.,
Crospovidone (Polyplasdone XL, Kollidon CL)
Mechanism of action: swelling, water wicking and possibly some deformation recovery.
Effective Concentration: 2-4%
3. Modified Cellulose – cross-linked form of Sodium carboxymethyl cellulose internally.
i.e., Ac-Di-Sol (Accelerates Dissolution), Nymcel
Mechanism  of  action:  wicking  because  of  fibrous  structure,  swelling  with  minimum
gelling. 
Effective Concentration: 1-3% (Direct Compression), 2-4% (Wet Granulation)
Advantages:
 Effective in lower concentration than starch.
 Less effect on compressibility and flow ability.
14
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 More effective intragranularly.
Disadvantages:
 More hygroscopic (may be problem with moisture sensitive drugs)
 Some are anionic and may cause slight in vitro binding with cationic drugs (not a
problem in vivo)
Excipients used in the formulation of chewable tablets6,10:
Excipients are inert (unreactive) substances used as diluents or vehicles for a drug. In the
pharmaceutical industry it is a catch all term which various sub-groups comprising diluents
or  fillers,  binders  or  adhesives,  disintegrants,  lubricants,  glidants,  flavors,  colors  and
sweeteners. All of these must meet certain criteria as follows:
 They must be physiologically inert
 They must be acceptable to regulatory agencies
 They must be physiologically and chemically stable.
 They must be free of any bacteria considered to be pathogenic or otherwise        
            objectionable.
 They must not interface with the bioavailability of the drug.
 They must be commercially available in the form and purity commensurate to  
            pharmaceutical standards.
 Cost must be relatively inexpensive.
 They must conform to all regulatory requirements.
To assure that no excipient interferences with the utilization of the drug, the formulator must
carefully and critically evaluate combinations of the drug with each of the contemplated
excipients and must have certain compliance of each ingredient with existing standards and
regulations.
The screening of drug-excipient and excipient-excipient interactions should be carried out
routinely in pre formulation studies.
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              Table No 2: List of excipients used in the formulation of chewable tablets
Excipients                       Functions               Examples
Diluents Diluents  are  fillers  used  to  make
required bulk of tablet
Lactose,  Microcrystalline
cellulose, Mannitol etc.
Binders Binders  are  used  to  impart
cohesive  qualities  to  powdered
materials.
Gelatin,  Glucose,  Acacia,  ethyl
cellulose,  hydroxypropyl
methyl cellulose etc.
Superdisintegrants They  facilitate  tablet  breaking
when  it  comes  in  contact  with
water in oral cavity/GIT
Croscarmellose  sodium,
Crospovidone,   Sodium  starch
glycolate, Starch etc.
Lubricants These  are  added  to  prevent
adhesion  of  tablet  material  to
surface  of  dies  and  punches
reduces inter particulate friction.
Magnesium  sterate,  Talc,
Paraffin, sodium  lauryl sodium,
etc.
Glidants These are added to improve flow
characteristics of powder mixture.
Glidant  minimize  the  friction
between particles.
Colloidal  Silicon  dioxide
(Aerosil), Corn starch, Talc etc.
Sweeteners These  are  added  to  produce  a
palatable dosage form. 
Sucrose,  Saccharin,  Aspartame,
etc.
Flavours These are added to improve taste
of dosage form
Peppermint,  Vanilla,  Orange,
Cinnamon, Mango, Cherry etc.
Colours These  are  added  for  better
appearance of dosage form
Sunset  yellow  (Supra),Ferric
oxide.
   
 Packaging of chewable tablets:
Some of the chewable tablets are stable during storage,  e.g.  for  18 months  or even 24
months  in  conventional  packaging  and  these  type  of  dosage  forms  are  stored  in  HDPE
bottles and  blister packs.
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  Some examples of chewable tablets 6:
 Acetaminophen chewable tablets 
 Common antacid chewable tablets 
 Children,s  buffered aspirin chewable tablets.
 Chewable multivitamin tablets. 
 Vitamin c chewable tablets. 
 ASTHMA 11, 12:
Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular
elements play a role: in particular,  mast cells, eosinophils, T lymphocytes,  macrophages,
neutrophils,  and  epithelial  cells.  In  susceptible  individuals,  this  inflammation  causes
recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at
night or in the early morning. These episodes are usually associated with widespread but
variable airflow obstruction that is often reversible either spontaneously or with treatment.
The  inflammation  also  causes  an  associated  increase  in  the  existing  bronchial
hyperresponsiveness to a variety of stimuli. 
Airflow obstruction (excessive airway narrowing) in asthma result in the  contraction of the
airway smooth muscle and swelling of the airway wall due to:
• Smooth muscle hypertrophy and hyperplasia
• Inflammatory cell infiltration
• Oedema
• Goblet cell and mucous gland hyperplasia
• Mucus hypersecretion
• Protein deposition including collagen
• Epithelial desquamation.
This  inflammatory process  can  cause  the  permanent  changes  in  the airways.  Long-term
changes include:
 Increased smooth muscle.
 Increase in bronchial blood vessels.
 Thickening of collagen layers.
 Loss of normal distensibility of the airway.
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Fig No 3:    Air flow obstruction in asthma 
Types of Asthma13
• Extrinsic asthma
• Intrinsic asthma
• Mixed asthma
• Cough variant asthma:
• Nocturnal asthma
• Gastro-esophageal asthma
Extrinsic asthma:
 Extrinsic asthma is also known as atopic asthma or allergic asthma. It is the most common
form of asthma in all age group. It usually affects young age group. 
People with allergic asthma and their family members frequently have other allergy related
problems such as fever, skin rashes, hives, eczema, and rhinitis.
Intrinsic asthma: 
18
                                                                                                                          Introduction
The intrinsic asthma is not related with the allergies.  In fact  it is caused by inhalation of
certain  chemical  such as  cigarette  smoke,  fumes of  motor  vehicles  and factories,  strong
odours, intake of certain medicines like aspirin; chest infections, stress, laughter, exercise,
cold  air,  food  preservatives  like  azinomoto  or  a  myriad  of  other  factors.
Antibodies are not produced by the body and the cause of developing intrinsic asthma may
be the irritation of the nerves or muscle in the airway.
Mixed asthma:
 It is mixture of allergic asthma and intrinsic asthma. These people react to some allergies
but their asthma is also triggered by other things also. For example symptoms are aggravated
in an asthmatic while facing the chest infection
Cough variant asthma:
Cough may be the sole manifestation of asthma or a distressing symptom. Although chronic
cough can be a sign of many health problems, it may be the principal or only manifestation
of asthma, especially in young children.
Nocturnal asthma:
 Nocturnal asthma is defined as an overnight fall of more than 20% in the FEV1 or PEFR.
This night time propensity is due to a number of reasons:
• Exposure to dust mite, animal dander.
• Gastro-esophageal reflux.
• Post nasal drip.
• Decreased cortisol level.
• Increased parasympathetic activity.
• Increased level of histamine.
• Increased sensitivity to histamine.
• The effect of medicines may wear off.
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• Early morning fall in circulating adrenaline.
• Overnight changes in vagal tone.
Gastro-esophageal asthma: 
Asthma may  be  caused  or  worsened  by  to  gastro-esophageal  reflux.  The  symptoms  of
GERD are common in both children and adults who have asthma. Medical management of
GERD includes:
• Avoiding heavy meals, fried food, caffeine, and alcohol.
• Avoiding food and drink within 3 hours of retiring.
• Elevating the head of the bed on 6- to 8-inch blocks.
• Using appropriate pharmacologic therapy.
Exercise Induced Asthma:
 Exercise  induced  asthma only  refers  to  asthma  that  occurs  only  with  exercise.
Before exercise pulmonary functions tends to  be normal,  but  within 5  to 10 minutes of
exercise they tend to fall. Pulmonary functions comes back to normal after rest but some
times tend to remain low for a longer time.
 
DRUGS USED IN ASTHMA14, 15: 
Basic pharmacology of agents used in treatment of asthma 
            The drugs most used for management of asthma are adrenoceptor agonist  or
sympathomemetic agents (used as relievers or bronchodilators) and inhaled corticosteroids
(used as controllers or anti-inflammatory agent)
SYMPATHOMIMETIC AGENTS:
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           Sympathomemetic agents  relax airway smooth muscles and inhibit  release of
bronchoconstricting mediators from mast cells. They may also inhibit microvascular leakage
and increase mucociliary transport by increasing ciliary activity. Sympathomimetic agents
are Epinephrine, Ephedrine, Isoproterenol and Albuterol as they increase the rate and force
of cardiac contraction.
BETA2 SELECTIVE DRUGS:
            The  β2-  selective  aderenoceptor  agonist  drugs  are  the  most  widely  used
sympathomimetic  for  the  treatment  of  asthma.  They  are  effective  after  inhaled  or  oral
administration  and  have  a  long  duration  of  action.  Some  of  the  drugs  are  Albuterol,
Terbutaline, Metaproterenol and Pirbuterol.
 A new generation of long lasting β2 selective agonist include Salmeterol and Formoterol.
METHYLAXANTHINE DRUGS: 
         The three important methylxanthines are Theophyline, Theobromine and Caffeine.
Theophylline  is  most  effective  bronchodilator  and  relieves  airflow  obstruction  in  acute
asthma and reduces the severity of symptoms.
CORTICOSTEROIDS:
       They have been used to treat asthma by their broad anti-inflammatory cytokenins. They
reduce bronchial reactivity and reduce the frequency of asthma exacerbation. 
Examples-Beclomethasone, Buderonide, Fluticasone, Mometasone and Triamcinolone.
 
LEUKOTRIENE PATHWAY INHIBITORS: 
      Leukotriene results from the action of  5-lipoxygenase on arachidonic acid and are
synthesized by a variety of inflammatory cells in the airways including eosinophils, mast
cells,  macrophages  and  basophils.  Leukotriene  B4(LTB4)  is  a  potent  neutrophil  chemo
attractant. Examples-Zileuton, Ziafirlukast and Montelukast
The principal  advantage  is  that  they are  taken  orally.  Some patients-especially  children
comply poorly with inhalation. 
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                                  LITERATURE REVIEW 
• Janugade B.U  et.al.,16 designed  an  oral  press-coated  tablet  was  prepared by using direct
compression and wet granulation methods to achieve the predetermined lag time. The tablet
contained Montelukast sodium in the inner core was formulated with an outer barrier layer by
different compositions of hydrophobic polymer ethylcellulose and hydrophilic polymer low-
substituted hydroxypropylcellulose in different concentrations. From lag time it was observed
that  lag  time  decreases  with  increasing  concentration  of  low-substituted
hydroxypropylcellulose.The tablets coated by wet granulation method gives less lag time as
compared to dry mixing blend method.
• Ajay et.al.,17 formulated  a   mouth  dissolving  tablets  of  Montelukast  sodium  by  direct
compression  method  using  superdisintegrants  such  as  croscarmellose  sodium  and
crospovidone. The compatibility of the drug in the formulations was confirmed by IR studies.
The formulations were subjected to precompression and postcompression parameters and the
results were found to be within acceptable limits. The formulated tablets disintegrated in less
than  26.33sec  fulfilling  the  official  requirements  for  dispersible  tablets.  The  rapid  drug
release was observed in the formulations containing croscarmellose sodium. Finally, it can be
concluded that mouth dissolving tablets of Montelukast sodium can be prepared by direct
compression method using croscarmellose sodium as superdisintegrant.   
        
• Surender  et.al.,18 Formulated    and  evaluated  colonic  pulsatile  release  matrix  tablets  of
Montelukast  sodium.  It  was  formulated  by  wet  granulation  method  using  different
combinations of HPMC K4M and K15M with varying amount of croscarmellose sodium,
formulation was evaluated for  in vitro tests  such as hardness,  friability,  weight  variation,
disintegration and dissolution. The formulation was evaluated for drug release mechanism by
applying Zero, First, Higuchi and Peppas kinetic models and selection was based on that of
linearity. Dissolution data revealed that formulations having HPMC K4M : K15M in ratio of
20: 0 along with croscarmellose sodium at a level of 2.4% given a release rate of more than
85% in 12h of duration. Drug release data fits well to zero order kinetics and mechanism of
drug release was found to be combination of swelling and erosion.
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• Ajay  Patil et.al.,19 developed fast  dissolving  films  of  Montelukast  sodium  by  using
microcrystalline cellulose as superdisintegrant and crospovidine as plasticizer. Result showed
that formulation F2 and F5 with 4% crospovidine and 10% microcrystalline cellulose gives a
better dissolution profile at the end of 30 minutes.
• N.G Raghavendra et.al.,20 performed a study to improve the improve the bioavailability and
efficacy by designing tablets-filled-capsule system. System comprise of different  doses of
immediate release tablets (IRT) and sustained release tablets (SRT) contained in a HPMC
capsule.  The drug-loaded core  tablets  were  produced  by wet  granulation  technique using
alcoholic solution of PVP K-30 as a binder. All the pre and post-compression  parameter
were  evaluated.  From  this,  study  it  was  concluded  that,  tablets-filled-capsule  systems
containing Montelukast sodium showed both sustained release as well as immediate release
may improve the bioavailability and efficacy.
• Ahmed B.Eldin et.al.,21 developed and evaluated a simple, sensitive and accurate stability
indicating analytical  method for Montelukast.  The chromatogram was performed with the
mobile  phase  containing  a  mixture  of  acetonitrile  and  0.01M  potassium  dihydrogen
phosphate. Validation was done for linearity, accuracy and precision and showed that method
is useful for routine quality control analysis and stability testing.
• Khan et.al.,22 evaluated the process for preparing a chewable tablet of loratidine comprising a
micronized form of an active ingredient, by combining the active ingredient with excipients
by geometric  dilution to form a final  mixture and applying direct  compression at  least  a
portion of the final mixture to form at least one tablet.
• Shaik et.al.,23 assessed the efficacy of Mebendazole in treatment of worm infestations in both
humans  and  animals.  The  chewable  tablets  of  Mebendazole  were  prepared  by  using
excipients as lactose or mannitol along with sodium starch glycolate in concentration ratios.
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From the disintegration studies, it was observed that the formulation containing lactose shows
less disintegration time than formulation containing mannitol.
• Rao N.G et.al.,24 formulated the buccal patches Montelukast sodium used in treatment of
chronic  asthma  attacks.  The  buccal  patches  were  prepared  by  using  hydrophilic  and
hydrophobic polymers.  The evaluation  were characterized for number of parameters like
physical  appearance and surface  texture,  weight  uniformity,  thickness,  folding endurance,
swelling  index,  surface  pH,  drug  content  uniformity,  in  vitro  residence  time,  bursting
strength,  drug–excipients  interaction  study,  and  in  vitro  drug  release  study.In-vitro
dissolution was studied and was observed that patches followed zero-order and mechanism
was diffusion rate limited and founded drug release in the range of 68.83 - 92.22 % in 8 hrs.
• Swati Jagdale et.al.,25 evaluated chewable tablet of levamisole which is used in the treatment
of  worm  infestations.  As  an  anthelmintic,  it  probably  works  by  targeting  the  nematode
nicotinergics acetylcholine receptor.  The chewable tablets of levamisole were prepared by
using  lactose  or  mannitol  along  with  sodium  starch  glycolate  in  concentration  ratios
especially for paediatric use. Sodium saccharin and vanilla were used as sweetening agent
and flavouring agent respectively.  It  was observed that the formulation containing lactose
shows less disintegration time than formulation containing mannitol.
• Kathiresan K  et.al.,26 formulated and evaluated 5 batches of loratadine chewable tablets.
Loratadine,  which  is  histamine  H1  receptor  antagonist  used  in  the  treatment  of  allergic
rhinitis and urticaria.  Results showed that thickness, weight variation, friability,  hardness,
and content uniformity of all 5 formulations were within the acceptance limits. But in the in-
vitro dissolution study, formulations 1, 2, and 5 demonstrated better cumulative drug release
than  formulations  3  and  4.  However,  cumulative  drug  release  of  formulation  5  was
comparable  with  innovator  than  formulations  1  and  2.  Hence  the  study  concludes  that
loratadine chewable tablet  formulated using avicel  CE 15 and starch paste showed better
characteristics of chewable tablets.  
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• Bharat  et.al.,27 performed  a  prospective  study of  Albendazole  which  is  a  benzimidazole
derivative with broad spectrum anthelmenthic activity and excellent tolerability. Orally it is
rapidly absorbed and metabolized to sulfoxide and sulfone, which may be responsible for its
anthelmenthic  action.  Albendazole  chewable  tablets  (400  mg)  were  prepared  by  three
methods  viz.  non aqueous granulation, aqueous granulation and direct compression. Tablet
prepared by these three methods were evaluated by the different parameters such as Average
weight, Hardness, Carr’s index, Tapped density, Friability, Disintegration, Water content, In
vitro dissolution etc.  All the parameters were found within the specifications. The study on
the  dissolution  profile  revealed  that  the  product  by  ‘Direct  Compression’  had  faster
dissolution rate while compared to remaining batches and marketed product and the assay
values were within the limits of 90% to 110%.
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                           AIM AND OBJECTIVE OF WORK
Aim:
 Montelukast sodium is used in the treatment of asthma. The usual dose is 4mg, 5mg and 10mg
to children and adults.  Now the present aim is to formulation and development of chewable
tablets  using different  concentration of  disintegrants  to  improve  the  onset  of  action and  the
bioavailability in the treatment of asthma.
Objectives:
I. To find  out  suitable concentration of  disintegrant  for  the  formulation of  Montelukast
sodium chewable tablets.
II. To  evaluate  the  pre-compression  parameters  such  as  bulk  density,  tap  density
compressibility index and hausner’s ratio.
III. To  evaluate  the  post  compression  parameters  such  as  physical  appearance,  hardness,
thickness, average weight, friability, disintegration time and assay.
IV. To perform In vitro dissolution studies and compare with that of innovator product.
V. To perform the stability study under the accelerated condition.
VI. To mask the bitter taste of Montelukast sodium by converting into a chewable tablets.
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                                                             PLAN OF WORK
The study was planned to carry out as follows,
1. Preparation  of  mixed  blend  of  drug  and  excipients  by  using  superdisintegrant
Croscarmellose sodium in the concentration of 1% to 4% by direct compression and
wet granulation technique.
2. Checking Drug and Excipient compatibility by FTIR Studies
3. Pre compression studies, like
a. Angle of repose 
b. Bulk density
c. Tapped density
d. Compressibility index
e. Hausner’s ratio
4. Preparation of chewable tablets.
5. Evaluation of prepared tablets
a. Appearance
b. Weight variation test
c. Hardness 
d. Thickness 
e. Friability 
f. Disintegration
g. Water content 
h. Assay
i. Dissolution 
j. Stability studies 
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                                                      DRUG PROFILE 
MONTELUKAST SODIUM 28
Category : Antiasthmatic
Molecular formula : C35H35ClNNaO3S
Molecular weight : 608.17 
Structural formula :
               
NCl
.
HO
COO-Na+
S
 
Chemical name: 2-[1-[1(R)-[3-[2(E)-(7-Chloroquinolin- 2-yl) vinyl] phenyl]-3-[2-hydroxy-
1- methylethyl) phenyl] propylsulfanylmethyl] cyclopropyl] acetic acid sodium salt
Description: Off white to pale yellow coloured powder.
Solubility: Soluble in water, methanol and ethanol and practically insoluble in acetonitrile.
Mechanism of action29: 
 The  cysteinyl  leukotrienes  (LTC4,  LTD4,  LTE4)  are  products  of  arachidonic  acid
metabolism and are released from various cells, including mast cells and eosinophils. These
eicosanoids bind to cysteinyl  leukotriene (CysLT) receptors.  The CysLT type-1 (CysLT1)
receptor is found in the human airway (including airway smooth muscle cells and airway
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macrophages)  and  on  other  pro-inflammatory  cells  (including  eosinophils  and  certain
myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and
allergic  rhinitis.  In  asthma,  leukotriene-mediated  effects  include  airway  edema,  smooth
muscle contraction, and altered cellular activity associated with the inflammatory process. In
allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during
both early-  and late-phase reactions and are associated with symptoms of allergic rhinitis.
Intranasal  challenge with CysLTs has been shown to increase nasal airway resistance and
symptoms of nasal obstruction. Montelukast is an orally active compound that binds with
high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically
important  airway receptors,  such as the prostanoid, cholinergic,  or β-adrenergic receptor).
Montelukast  inhibits physiologic actions  of  LTD4  at  the  CysLT1  receptor  without
any agonist activity.
Pharmacodynamics: 
Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by
the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics. Doses as low as
5  mg  cause  substantial  blockage  of  LTD4-induced  bronchoconstriction.  In  a  placebo-
controlled,  crossover  study  (n=12),  montelukast  inhibited  early-  and  late-phase
bronchoconstriction due to antigen challenge by 75% and 57%, respectively.
Pharmacokinetics:
Absorption: 
Montelukast  is  rapidly  absorbed  following  oral  administration.  Mean  peak  plasma
concentration (Cmax) is achieved 3 hours (Tmax) after  administration in adults  in the fasted
state.  The  mean  oral  bioavailability  is  64%.  The  oral  bioavailability  and  Cmax are  not
influenced by a standard meal.
Distribution:
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Montelukast  is  more  than  99%  bound  to  plasma  proteins.  The  steady-state  volume  of
distribution of Montelukast averages 8 – 11 liters. 
Metabolism:
 Montelukast is extensively metabolized in liver by cytochrome P450 isoenzyme CYP3A4,
CYP2A6 and CYP2C9
Excretion: 
The plasma clearance of montelukast averages 45 mL/min in healthy adults. Following an
oral dose of radiolabeled montelukast, 86% of the radioactivity was recovered in 5-day fecal
collections and <0.2% was recovered in urine. Coupled with estimates of montelukast oral
bioavailability,  this  indicates  that  montelukast  and  its  metabolites  are  excreted  almost
exclusively via the bile.
Dosage and administration:
 The dosage for adults and adolescents 15 years of age and older is one 10-mg tablet. 
 The dosage for pediatric patients 6 to 14 years of age is one 5-mg chewable tablet. 
 The dosage for pediatric patients 2 to 5 years of age is one 4-mg chewable tablet or
one packet of 4-mg oral granules. 
 The dosage for pediatric patients 6 to 23 months of age is one packet of 4-mg oral
granules.
Overdosage:
Abdominal pain, headache, psychomotor hyperactivity, somnolence, thirst, vomiting.
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CONTRAINDICATIONS 
 Hypersensitivity to any component of this product
 Status asthmaticus
Drug Interactions
 Gemfibrozil:  Montelukast  plasma  concentrations  may  be  elevated,  increasing  the
pharmacologic effects and risk of adverse reactions. Monitor the clinical response and
adjust the montelukast dose as needed.
 Prednisone:  Adverse effects of prednisone (Eg. edema) may be increased. Monitor
the clinical response. If an interaction is suspected, consider discontinuing one or both
agents.
 Strong  CYP2C9  and  CYP3A4  inducers  (Eg,  phenobarbital,  rifampin):  May
decrease montelukast levels. Monitor the clinical response and adjust the montelukast
dose as needed.
Side effects:
Montelukast has manageable side effects such as given below:
 Severe allergic reactions such as rash; hives; itching; difficulty breathing; tightness in
the chest; swelling of the mouth, face, lips, or tongue;   headache (18% to 20%) and
dizziness (2%).
 Gastrointestinal:  Gastrointestinal  side  effects  have  included  abdominal  pain,
dyspepsia,  or infectious  gastroenteritis  in up to 3% of patients.  Diarrhea has been
associated with the use of higher than recommended doses 
 Respiratory:  Respiratory system side effects have included influenza (4%), cough
(3%), and nasal congestion (2%). In some studies, upper respiratory tract infection
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(28%) and worsened asthma (4% to 11%) were associated with the use of this drug.
However,  many patients with  asthma have some or all  of  these symptoms,  and a
causal  relationship  has  not  been  proven.  Rhinorrhea,  sinusitis,  otitis,  influenza,
epistaxis, and pneumonia have also been reported.
 Ocular: Ocular side effects have included conjunctivitis.
 Other: Other side effects have included isolated cases of Churg-Strauss syndrome, a
rare systemic vasculitis associated with asthma.
PRECAUTIONS 
 It  is  not  a  fast-acting asthma  medication and  cannot  replace  fast-acting  rescue
inhalers. Do not use montelukast to treat an asthma attack.
 Some reports  were  studied  that  who  were  taking  an  oral  steroid  may be  able  to
decrease or stop this medication when starting montelukast. 
 Chewable montelukast  tablets contain phenylalanine.  This is important  information
for people with phenylketonuria   (PKU) is a rare condition in which a baby is born
without the ability to properly break down an amino acid called phenylalanine.), who
must limit their phenylalanine intake.
 In  some  it  can  cause  liver  damage.  So  care  should  be  taken  while  taking  the
medication. 
 Patients with known aspirin sensitivity should be advised to continue avoidance of
aspirin  or  nonsteroidal  anti-inflammatory  agents  while  taking  montelukast  sodium
drug.
Storage/Stability
 Store between 59° and 86°F. Protect from moisture and light.
Administration:
Give with or without food.
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Table No 3:  Route of administration
Route Onset Peak Duration
P.O. Unknown 3-4 hr Unknown
P.O. (chewable) Unknown 2-2.5 hr Unknown
P.O. (granules) Unknown Unknown Unknown
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                                               EXCIPIENT PROFILE
  
1.MICROCRYSTALLINE CELLULOSE30
Non-proprietary Names
BP: Microcrystalline cellulose
PhEur: Cellulose microcrystalline
Synonym: Cellulose gel, crystalline cellulose,E460, Emcocel, Fibrocel, Tablose,  Vivacel.
Chemical Name : Cellulose
Empirical formula : (C6H10O5)n where n ≈ 220
Molecular weight  : 36000
Melting Point  : 260-270⁰C
Particle size: (MCC pH102) = 100 µ m
Description:  MCC  is  purified,  partially  depolymerized  cellulose  that  occur  as  a  white,
odorless,  crystalline powder composes  of  porous particle.  It  is  commercially available in
different particle size and moisture grades that have different properties and application. 
Functional  Category:  Adsorbent,  suspending  agent,  tablet  and  capsule  diluent,  tablet
disintegrants.
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                                Table No 4: Uses of Microcrystalline Cellulose
Use Concentration (%)
Adsorbent 20-90
Antiadherent 5-20
Capsule binder/ diluents 20-90
Tablet disintegrant 5-15
Tablet binder/ diluents 20-90
Stability and Storage: It is stable though hygroscopic material. The bulk material should be
stored in well closed container in a cool and dry place.
Incompatibility: It is incompatible with strong oxidizing agent.
2.MANNITOL30
Nonproprietary Name: 
 BP: Mannitol
 JP: D-Mannitol
 PhEur: Mannitolum
 USP: Mannitol
Synonyms: Cordycepic  acid; E421;  manna  sugar;   D-mannite;  mannite;  Mannogem;
Pearlitol
Chemical Name :  D-Mannitol
Empirical Formula : C6H14O6
 Molecular Weight : 182.17
Structural Formula:
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Functional Category: Diluent, sweetening agent
Applications in Pharmaceutical Formulation or Technology:
Mannitol is widely used in pharmaceutical formulations and food products. In pharmaceutical
preparations it is primarily used as a diluent (10–90% w/w) in tablet formulations, where it is
of particular value since it is not hygroscopic and may thus be used with moisture-sensitive
active ingredients. 
Mannitol may be used in direct-compression tablet applications, for which the granular and
spray-dried forms are available,  or  in wet  granulations.  Granulations  containing mannitol
have  the  advantage  of  being  dried  easily.  Specific  tablet  applications  include  antacid
preparations, glyceryl trinitrate tablets, and vitamin preparations. 
Mannitol  is  commonly  used  as  an  excipient  in  the  manufacture  of  chewable  tablet
formulations because of its negative heat of solution, sweetness, and ‘mouth feel’. 
Description:
Mannitol is  D-mannitol. It is a hexahydric alcohol related to mannose and is isomeric with
sorbitol. Mannitol occurs as a white, odorless, crystalline powder, or free-flowing granules. It
has a sweet taste, approximately as sweet as glucose and half as sweet as sucrose, and imparts
a cooling sensation in the mouth.
3. CROSCARMELLOSE SODIUM30
Nonproprietary Names:
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BP: Croscarmellose sodium
PhEur: Carmellosum natricum conexum
USPNF: Croscarmellose sodium
Synonyms  :  Ac-Di-Sol;  crosslinked  carboxymethylcellulose  sodium;  Explocel;  modified
cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol.
 Chemical Name :  Cellulose, carboxymethyl ether, sodium salt, crosslinked
Functional Category :  Tablet and capsule disintegrant.
Applications in Pharmaceutical Formulation or Technology
Croscarmellose  sodium is  used  in  oral  pharmaceutical  formulations  as  a  disintegrant  for
capsules, tablets, and granules. 
In tablet formulations, croscarmellose sodium may be used in both direct-compression and
wet-granulation processes. When used in wet granulations, the croscarmellose sodium should 
be added in both the wet and dry stages of the process (intra- and extragranularly) so that the
wicking and swelling ability of the disintegrant is best utilized. Croscarmellose sodium at
concentrations up to 5% w/w may be used as a tablet disintegrant, although normally 2% w/w
is used in tablets prepared by direct compression and 3% w/w in tablets prepared by a wet-
granulation process. 
                                       Table No 5:  Uses of croscarmellose sodium
Use Concentration (%)
Disintegrant in capsules 10–25
Disintegrant in tablets 0.5–5.0
Description: Croscarmellose sodium occurs as an odorless, white or greyish white powder.
Stability and Storage Conditions:  Croscarmellose sodium is a stable though hygroscopic
material.  A model tablet  formulation prepared by direct  compression, with croscarmellose
sodium as a disintegrant, showed no significant difference in drug dissolution after storage at
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300C for 14 months. Croscarmellose sodium should be stored in a well-closed container in a
cool, dry place.
 Incompatibilities:  The efficacy of disintegrants,  such as croscarmellose sodium, may be
slightly  reduced  in  tablet  formulations  prepared  by  either  the  wet-granulation  or  direct-
compression process  that  contain hygroscopic excipients  such as sorbitol.  Croscarmellose
sodium is not compatible with strong acids or with soluble salts of iron and some other metals
such as aluminum, mercury and zinc.
4.ASPARTAME30
Nonproprietary Names:
 BP: Aspartame
 Ph Eur: Aspartamum 
 USPNF: Aspartame                                          
Synonyms:   3-Amino-N-(α-carboxyphenethyl) succinamic acid N- methyl ester; 3-Amino-
N-(α- methoxycarbonyl phenethyl)  succinamic acid; Aspartyl pheylamine methyl ester; 
Chemical name :    N-α-L-Aspartyl-L-phenylalanine 1-methyl ester.
Emperical formula :    C14H18N2O5       
Molecular weight :     294.31
Functional category :    Sweetening agent
Applications in Pharmaceutical Technology:
                   Aspartame is used as an intense sweetening agent in beverage products, food
products, table top sweeteners and in pharmaceutical preparations including tablets, powder
mixes and vitamin preparations It enhances flavour systems and can be used to mask some
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unpleasant taste characteristics; the approximate sweetening power is 180-200 times that of
sucrose. Therapeutically, aspartame is used in the treatment of sickle cell anemia.
Description: Aspartame occurs as an off white, almost odorless crystalline powder with an
intensely sweet taste.
Solubility: Slightly  soluble  in  ethanol  (95%),  sparingly  soluble  in  water.  At  200C  the
solubility  is  1%w/v  at  the  isoelectric  point  (pH  5.2).  Solubility  increases  at  higher
temperatures and at more acidic pH, e.g. at pH 2 and 200C solubility is 10%w/v.
5. MAGNESIUM STEARATE30
Nonproprietary names:
BP: Magnesium Stearate                                                                                                            
JP: Magnesium Stearate
Ph Eur: Magnesii stearas
USPNF: Magnesium Stearate 
 Synonyms:  Magnesium octadecananoate; Octadecanoic acid; Magnesium salt; Stearic acid,
magnesium salt.
Chemical name:  Octadecanoic acid magnesium salt
Emperical formula:  C36H70MgO4         
Molecular weight:  591.34
Functional category:  Tablet and capsule lubricant.
Applications  in  Pharmaceutical  Technology:  Magnesium  stearate  is  widely  used  in
cosmetics,  foods,  and pharmaceutical  formulations.  It  is  primarily used  as  a  lubricant  in
capsule and tablet manufacture at concentrations between 0.25 and 5%w/w. It is also used in
barrier creams.
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Description: Magnesium stearate is a fine, white, precipitated or milled, Impalpable powder
of low bulk density, having a faint odour or and a characteristic taste. The powder is greasy to
the touch and readily adheres to the skin.
Solubility: Practically insoluble in ethanol, ethanol (95%), ether and water, slightly soluble in
warm benzene and warm ethanol (95%).
6. HYDROXY PROPYL CELLULOSE30
Nonproprietary Names
BP: Hydroxypropylcellulose
JP: Hydroxypropylcellulose
PhEur: Hydroxypropylcellulosum
USPNF: Hydroxypropyl cellulose
 Synonyms: Cellulose, hydroxypropyl ether; E463; hyprolose; Klucel; Methocel; Nisso HPC;
oxypropylated cellulose.
 Chemical Name: Cellulose, 2-hydroxypropyl ether 
Empirical Formula: [CH2CH(CH3)O]mH
Molecular Weight: 50 000–1 250 000;
Structural Formula:
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                                             R is H or [CH2CH(CH3)O]mH
Functional Category:
Coating  agent;  emulsifying  agent;  stabilizing  agent;  suspending  agent;  tablet  binder;
thickening agent; viscosity-increasing agent.
Applications in Pharmaceutical Formulation or Technology:
Hydroxypropyl cellulose is widely used in oral and topical pharmaceutical formulations; 
In oral products,  hydroxypropyl cellulose is primarily used in tableting as a binder,  film-
coating, and extended-release-matrix former. Concentrations of hydroxypropyl cellulose of
2–6% w/w may be used as  a  binder  in either  wet-granulation or  dry,  direct-compression
tableting processes. Concentrations of 15–35% w/w of hydroxypropyl cellulose may be used
to produce tablets with an extended drug release. The release rate of a drug increases with
decreasing  viscosity  of  hydroxypropyl  cellulose.  The  addition  of  an  anionic  surfactant
similarly increases the viscosity of hydroxypropyl cellulose and hence decreases the release
rate of a drug. Typically, a 5% w/w solution of hydroxypropyl cellulose may be used to film-
coat tablets. Aqueous solutions containing hydroxypropyl cellulose along with an amount of
methyl cellulose or ethanolic solutions have been used. Hydroxypropyl cellulose is also used
in microencapsulation processes and as a thickening agent. Hydroxypropyl cellulose is also
used in cosmetics and in food products as an emulsifier and stabilizer.
Description: Hydroxypropyl cellulose is a white to slightly yellow-coloured, odourless and
tasteless powder.
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Typical Properties: 
Melting point:
Softens at 130°C; chars at 260–275°C.
Moisture  content:  Hydroxypropyl  cellulose  absorbs  moisture  from the  atmosphere;  the
amount of water absorbed depends upon the initial moisture content and the temperature and
relative humidity of the surrounding air. Typical equilibrium moisture content values at 25°C
are 4% w/w at 50% relative humidity and 12% w/w at 84% relative humidity
Solubility:  Soluble 1 in 10 parts dichloromethane; 1 in 2.5 parts ethanol (95%); 1 in 2 parts
methanol; 1 in 5 parts propan-2-ol; 1 in 5 parts propylene glycol and 1 in 2 parts water.
Practically insoluble in aliphatic hydrocarbons; aromatic hydrocarbons; carbon tetrachloride;
petroleum distillates; glycerin; and oils.
7. Ferric  Oxide31
Synonyms
(a ) Iron oxide black:  black  magnetic oxide;  black oxide,  black  rouge; ethiopsiron; ferric
ferrous oxide;  ferrosoferric oxide;iron oxides(FeO); magnetite.
(b) Iron  oxide  red:  anhydrous  ferric  oxide;  anhydrous  iron(III)oxide;  diiron  trioxide;
hematite; red ferric oxide; Sicovit R30
(c) Iron oxide yellow monohydrate:  hydrated ferric oxide; iron (III) oxide monohydrate,
yellow ferric oxide; ferric hydroxide; iron hydrated; iron hydroxide; yellow iron oxide
Chemical Name: Iron oxides: Iron oxide black, Iron oxide red, Iron oxide yellow. 
Empirical Formula and Molecular Weight: 
(a) Fe3O4 : 231.54
(b) Fe2O3 : 159.70
(c) Fe2O3.H2O : 177.70 (monohydrate);  FeHO2 :  88.85(hydrate)
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Density :
Iron oxide black (Fe3O4):  5 .1 g / cm 3 
Iron oxide red (Fe2O3):     5 .2 g / cm 3
Iron oxide yellow (Fe2O3.H2O):  4 . 1 g / c m 3
Description: Iron oxides occur as yellow, red, black, or brown powder. The color depends on
the particle size and shape, and crystal structure.
Melting point : 15650C for iron oxide red (Fe2O3).
Solubility: Soluble in mineral acids; insoluble in water.
Stability and Storage Conditions: Iron oxides should be stored in well-closed containers in
a cool, dry place.
Incompatibilities:   Iron oxides have been reported to make hard gelatin capsules brittle at
higher  temperatures  when  the  residual  moisture  is  11–12%.  This  factor affects the
use of iron oxides for coloring hard gelatin capsules, and will limit the amount that can be
incorporated into the gelatin material.
Applications in Pharmaceutical Formulation or Technology:
Iron  oxides  are  widely used  in  cosmetics,  foods,  and  pharmaceutical  applications  as
colourants  and  UV  absorbers.  As  inorganic  colorants  they  are  becoming  of  increasing
importance as a result of the limitations affecting some synthetic organic dye stuffs. However,
iron oxides also have restrictions in some countries on the quantities that may be consumed,
and  technically  their  use  is  restricted  because  of  their  limited  color  range  and  their
abrasiveness.
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      MATERIALS AND METHODS
         LIST OF EQUIPMENTS:
         Table No 6: List of equipments
Equipment Manufacturer
Electronic balance Mettler-Toledo, USA
Bulk density apartments Electro lab, Mumbai
Rapid Mixer Granulator (RMG) Anchor Mark Pvt. Ltd.,
Tablet compression machine (single rotary 16
punches)
Cadmach  machinery  Co  Pvt
Ltd.,INDIA
Friability test apparatus Electro lab, Mumbai
Tablet dissolution apparatus Electro lab, Mumbai
Disintegration apparatus Electro lab, Mumbai
Blender Erweka
 Electronic Thickness Mitutoyo,Japan 
Hot air over Eltek motors, Mumbai
High  performance  liquid  chromatography
(HPLC)
Shimadzu Scientific Instruments 
Sieves Jayanth test sieves, Mumbai
Hardness tester Dr.Schleuniger pharmatron, USA
Fluidized bed dryer Anchor Mark Pvt. Ltd.,
Stability chamber Thermo labs 
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                                          LIST OF CHEMCALS
       Table No 7: List of chemicals
   Ingredients        Manufacturer           Supplier
Montelukast
sodium
M/s  Aptuit  Laurus  Private
Ltd., Hyderabad
M/s  Aptuit  Laurus  Private
Ltd, Hyderabad
Mannitol Colorcon, UK Ansul Agencies, Mumbai
Croscarmellose
sodium  
Maple Biotech Pvt. Ltd. Maple Biotech Pvt. Ltd
MCC PH 101 FMC Biopolymer, USA Signet Chemical Corporation,
Mumbai
MCC PH 102 FMC Biopolymer, USA Signet Chemical Corporation,
Mumbai
Hydroxypropyl
cellulose
Merck limited, Mumbai Vasco Scientifics Pvt. Ltd.,
Ferric oxide ISP Technologies INC,
USA
Signet Chemical Corporation
Mumbai
Magnesium sterate             _ Ferro Chemical Corporation
Cherry flavor Tridient  pharmaceuticals
Pvt.Ltd
Tridient  pharmaceuticals
Pvt.Ltd.
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                                                           METHODS  
 PREFORMULATION STUDIES
Drug-excipient compatibility studies: 32
The compatibility studies provide the scheme for the drugs combination with excipients in
the  fabrication  of  the  dosage  form.  The  study  was  carried  out  to  establish  that  the
therapeutically active drug has not undergone any changes,  after  it  has been subjected to
processing steps during formulation of tablets.
Compatibility studies were carried out by mixing definite proportions of Montelukast sodium
and  Mannitol, Cellulose microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose,
Magnesium  sterate,  Aspartame,  Ferric  oxide  and  Cherry  flavor  in  the  ratios  of
1:1,1:2.5,1:3,1:5,1:10 and kept in glass vials, which are stored at 500C(3 weeks).
FTIR Spectroscopy:33
All the excipients used in the different formulations were mixed with the drug separately in
equal
ratios and the samples of the final formula of the chewable tablet were analyzed through
FTIR  studies.  FT-IR  spectra  (400-4400cm-1)  were  obtained  on  a  Perkin-Elmer  FT-IR
spectrophotometer with a resolution of 4 cm-1. KBR pellets were prepared gently by mixing
the 1mg sample with 100 mg potassium bromide. The characteristic peaks were recorded.
Pre-compression parameters:32,34
a) Angle of repose:
The internal  angle  between the surface  of the pile of  blend and the horizontal  surface is
known as the angle of repose.
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Method:
The blend was passed through a funnel fixed to a burette stand at a height of 4 cm. A graph
paper  was  placed  below the  funnel  on  the  table.  The  height  and  radius  of  the  pile  was
measured. Angle of repose of the blend was calculated using the formula:
Angle of repose (θ) = tan-1 (h/r)
Where,
h = Height of the pile
r = Radius of the pile
b) Bulk density:
The bulk density is used as a measure to describe packing materials of granules.
Method:
Bulk density is the ratio of given mass of powder and its bulk volume. It was determined by
transferring  an accurately  weighed  amount (25 Gms) of  powder  sample to the graduated
cylinder with the aid of a funnel. The initial volume was noted. Ratio of weight of the sample
to the volume it occupied was calculated.
Bulk density = W/V0 g/ml
Where,
W = Mass of the blend
V0 = Untapped volume
c) Tapped density:
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Method
It  was  measured  by  transferring  a  known  quantity  (25  Gms)  of  blend  into  a  graduated
cylinder and was placed on the tapped density apparatus. The initial volume was noted. The
apparatus was set for 500, 750 and taps. The tapped density was determined as the ratio of
mass of the blend to the tapped volume.
Tapped density = W/Vf g/ml
Where,
W = Mass of the blend
Vf = Tapped volume
d) Compressibility index:
It is the property of a powder to be compressed.
Method:
It  is  measured  by  tapped  density  apparatus  for  500,  750  and  1250  taps  for  which  the
difference  should  be  not  more  than  2%.  Based  on the  apparent  bulk  density  and tapped
density  the  percentage  compressibility  of  the  blend  was  determined  using  the  following
formula.
           % Compressibility = [(Tapped density – Bulk density) / Tapped density] X 100
e) Hausner’s ratio:
It indicates the flow properties of the powder. The ratio of tapped density to the bulk density
of the powder is called Hausner’s ratio. 
Hausner ratio= Tapped density / Bulk density
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Table No 8: Flow properties and corresponding Angle of repose, compressibility index
and    Hausner’s ratio:
S.NO
Flow
prop
erties
Angle of response (θ) Compressibility 
Index (%)
Hausner’s ratio
1 Excellent 25-30 <10 1.00-1.11
2 Good 31-35 11-15 1.12-1.18
3 Fair 36-40 16-20 1.19-1.25
4 Passable 41-45 21-25 1.26-1.34
5 Poor 46-55 26-31 1.35-1.45
6 Very poor 56-65 32-37
1.46-1.59
7 Very very poor >66 >38 >1.6
Post compression parameters:
f) Physical Appearances:
The tablets were inspected for smoothness, absence of cracks,  chips an other undesirable
characteristics.If they are coloured, it includes examination for mottling and other evidence of
non uniform colour distribution except her they are intentionally. 
g) Weight variation test:35
20 tablets were randomly selected from each batch and their average weight was calculated
using digital balance. Individual weight of each tablet was also calculate using the same and
compared with the average weight.
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Table No 9: Weight variation requirements:
h) Thickness:
Thickness was determined for 20 pre- weighted tablets of each batch using a digital vernier
scale and the average thickness was determined in mm. The thickness of the tablets mostly
related to the tablet hardness and can be used as an initial control parameter.
a) Thickness:
Thickness was determined for 20 pre- weighted tablets of each batch using a digital vernier
scale and the average thickness was determined in mm. The thickness of the tablets mostly
related to the tablet hardness and can be used as an initial control parameter.
b) Percentage Friability:
The  friability  test  gives  an  indication  of  tablets  ability  to  rest  chipping  and  abrasion  on
handling during packaging and shipping. Usually for conventional tablets friability value of
1.0% or less is desirable. If the tablet weight is >_ 650 mg 10 tablets were taken and initial
weight was noted.  The tablets were rotate  in the Roche friabilator  for 100 revolutions at
25rpm. The tablets were dedusted and reweighed. 
The tablets that loose less than 1% weight were considered to be compliant.
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130 or less 10%
From 130 to 324 7.5%
>324 5%
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The percentage friability is expressed as the loss o weight and is calculated by the formula:
% Friability = (A-B/A) * 100
            Where,
A= Initial weight of tablets 
                                    B= Final weight of tablets after 100 revolutions
c) Disintegration time:35
Disintegration time is the time taken by a tablet to break up into granules of specified size (or
smaller), under carefully specified test conditions. The disintegration test is carried out in an
apparatus  containing  basket  rack  assembly  with  six  glass  tubes  of  7.75  cm  length  and
2.15mm in diameter the bottom of which consists of 10 mesh sieve. The basket is raised and
lowered 28-32 times per minute  in the medium of 900 ml which is maintained at +20C. Six
tablets were placed in each of the tubes and the time required for complete passage of tablet
fragments through the sieve (# 10) was considered as the disintegration time of the tablet.
d) Water content (By KF Method)
Instrument: Karl Fischer Titrator:
35 ml of mixture of methanol was transferred to the titration vessel and titrated with Karl
Fischer  reagent  to the  electrometric  point,  to  consume any moisture that  may be present
(disregard the volume consumed, since it does not enter into the calculation). Powder from 5
tablets was  used,  ground  to  a  fine  powder  in  an atmosphere  of  temperature  and relative
humidity  known  no  to  influence  the  results.  300-500  mg  of  the  powder  was  accurately
weighed and transferred into the titration vessel, mixed and titrated with Karl Fischer reagent
to the electrometric end point; finally the water content of the specimen in mg was calculated.
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e) Preparation of standard curve for Montelukast sodium:
Standard graph for Montelukast Sodium:
Accurately weigh and transfer about 55 mg of Montelukast working standard into a 100 ml
clean, dry volumetric flask, add about 70 ml of methanol and sonicate to dissolve. Dilute to
volume with methanol and mix.
f) Dissolution study (By HPLC method):
The dissolution test calibrates the rate of release of the drug from the dosage form in vitro; it
is usually expressed as extent  of dissolution (% drug content) occuring after certain time
under  specified  conditions.  For  effective  absorption  of  oral  solid  dosage  form,  simple
disintegration  of  the  dosage  form is  not  adequate  and  the  dissolution  of  the  drug to  the
surrounding medium plays a vital role. Though dissolution is not a predictor of therapeutic
efficacy it can be looked upon a tool which can provide valuable information about biological
availability of drug and batch to batch consistency. Dissolution is considered as one of the
most important quality control tests performed for pharmaceutical dosage form.
Instrument:  A High Performance Liquid Chromatograph System equipped with Photodiode
array detector and data handling system (Shimadzu scientific instruments).
 
Dissolution parameters:
Medium   : Purified water with 0.5% SLS
Volume   : 900ml
Temperature     : 370C + 0.50C
Apparatus         : USP Type-II (Paddle)
Rotating speed: 50RPM
Time point       : 30 minutes
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Chromatographic conditions:
Column : Hypersil BDS C8, 5µ (100 mm x 4.6mm) 
Pump mode : Isocratic
Flow rate : 2.0 ml/min
Detection : UV, 345 nm
Injection Volume : 20 µL 
Column temperature : 40°C
Run time                          : 10 minutes
Procedure:
The  in  vitro  dissolution  study  was  done  in  the  USP  dissolution  test  apparatus,  type  II
(paddle). One tablet was placed in each of the six dissolution flasks containing 900 ml of
dissolution  medium,  previously  maintained  at  370C  + 0.50C.  After  completion  of  each
specified time interval, 10ml of the solution was withdrawn from zone midway between the
surface of the dissolution medium and top of the rotating blade,  not less than 1 cm from
vessel  wall  and filtered  through 0.45µm membrane  filter.  The samples  were  collected  at
specified time intervals and diluted to required volume with dissolution medium and inject
the solution into chromatograms and record the chromatograms.
g) Assay (By HPLC method):
Instrument: A High Performance Liquid Chromatograph System equipped with Photodiode
array detector and data handling system (Shimadzu scientific instruments).          
Chemicals and reagents:
 Potassium Dihydrogen Orthophosphate   : AR grade
 Orthophosphoric acid (≈88 % w/w)         : AR grade
 Acetonitrile                      : HPLC grade
 Methanol           : HPLC grade
 Water                      : Milli-Q grade.
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Chromatographic conditions:
Column : Hypersil BDS C8, 5µ (100 mm × 4.6 mm) or equivalent 
Pump mode : Isocratic
Flow rate : 2.0 ml/min.
Detection : UV, 345 nm.
Column temperature : 40°C
Injection volume : 20 µL
Preparation of buffer:
Dissolve 6.8 g of potassium dihydrogen orthophosphate in 1000 ml of water. Adjust the pH
to 3.5 ± 0.05 with orthophosphoric acid. Filter through 0.45 µm nylon membrane filter.
Preparation of Mobile phase:
Prepare a degassed mixture of buffer and acetonitrile in the ratio of 45:55 v/v.
Diluent preparation:
Use mobile phase as a diluent.
Standard preparation:
 Accurately weigh and transfer about 50 mg of Montelukast working standard into a 100 ml
clean, dry volumetric flask, add about 70 ml of methanol and sonicate at room temperature to
dissolve. Dilute to volume with methanol and mix. Further dilute 5 ml of this solution to 50
ml with diluent and mix.  Filter through 0.45 µm nylon membrane filter. 
Sample preparation:
Weigh and transfer 10 tablets into a 250 ml clean, dry volumetric flask. Add about 170 ml of
diluent and sonicate for 30 minutes with intermittent shaking at room temperature. Dilute to
volume with diluent and mix. Centrifuge the solution at 10000 RPM for 10 minutes. Transfer
5 ml of supernatant solution into a 20 ml clean, dry volumetric flask, dilute to volume with
diluent and mix. Filter through 0.45 µm nylon membrane filter.
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Procedure:
Inject the sample solution, into the chromatograph. Record the chromatograms and measure
the peak areas. 
Calculation:
Calculate the amount of Montelukast by using the following formula:
                         AT         DS       P      
   Content of Montelukast =     -------- × -------- ×  ------- 
                  
(mg / tablet)             AS         DT          100
                                                 
         Content of Montelukast (mg/tablet)
     % Labeled amount =    ----------------------------------------------- × 100
                                     Label claim, in mg
Where,
AT = Average  area  count  of  Montelukast  peak  in  the  chromatogram of  sample
solution
AS = Average area count of five replicate injections for Montelukast peaks in the
chromatograms of standard solution, as obtained under system suitability
DS = Dilution factor of standard solution (weight ÷ dilution)
DT = Dilution factor of sample solution (weight ÷ dilution)
P = Percent potency of Montelukast working standard used (as is basis)
W = Theoretical weight of the blend, in mg. 
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SIMILARITY FACTOR AND DISSIMILARITY FACTOR CALCULATION36
The similarity factor (f2) was defined by CDER, FDA, and EMEA as the “logarithmic
reciprocal square root transformation of one plus the mean squared difference in percent 
dissolved between the test and reference release profiles”.
Dissimilarity (f1) describes the relative error between two dissolution profiles. It 
approximates the percent error between the curves. 
f1 = { [ å
 t=1 
n
½Rt – Tt ½ ] / [ å  t=1 n Rt ] } . 100
f2 = 50. log { [1 + ( 1/n) å
 t=1 
n
 (Rt - Tt ) 2 ] –0.5 . 100
The similarity factor f2 and its significance is shown in the following table
Table No 10.
Similarity factor F2 and its significance
S. No.
Similarity
factor
(F2)
Significance
1. <50 Test and reference profiles are dissimilar.
2. 50 -100 Test and reference profiles are similar.
3. 100 Test and reference profiles are identical.
4. >100 The equation yields a negative value.
ACCELERATED STABILITY STUDY OF OPTIMIZED FORMULATION: 37
            Stability of a pharmaceutical preparation can be defined as the capability of a
particular formulation in a specific container/closure system to remain within its physical,
chemical,  microbiological,  therapeutic and toxicological  specifications throughout its shelf
life.
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The purpose of the stability testing is to provide an evidence on how the quality of a
drug substance or drug product varies with time under influence of a variety of environmental
factors  such  as  temperature,  humidity  and  light,  and  enables  recommended  storage
conditions, re-test periods and shelf-lives to be established. 
ICH specifications for stability study:
 Long term testing: 250C ± 20C and 60%± 5% RH for 12 months.
 Accelerated testing: 400C ± 20C and 75%± 5% RH for 6 months.
Procedure:
In the present study, stability studies were carried out at 40  0C and 75% RH  for a
specific time period up to 60 days for optimized formulations. For stability study, the tablets
were  sealed  in  aluminum  packaging  coated  inside  with  polyethylene.  These  sample
containers were placed in desiccator’s maintained at 75% RH.
Evaluation of samples:
The samples were analyzed for the following parameters:
I. Physical evaluation:
Appearance: The samples were checked for any change in color at every month.
II. Chemical evaluation:
Drug content: The samples were checked for drug content.
Drug release: The samples were subjected to drug release studies.
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        EXPERIMENTAL INVESTIGATION
Table No 11:     Innovator product details:
Name of the product Singulair junior 
Manufacturer name Merck Sharp &Dohme Limited, Germany
Description Pink, round, debossedwith code`MSD275’ on one side and
`SINGULAIR’ on the other side.
Package PVC/aluminium blister pack 
Table No 12:   Physical parameters of innovator product: 
Parameters 5mg
Thickness(mm) 4.42
Hardness(kg/cm2) 2.8
Length(mm) 9.59
Width(mm) 9.66
Disintegration time (sec) 27
Table No 13:   Dissolution profile of innovator product (SINGULAIR JUNIOR)
Time(min) Drug Release percentage 
10 90
15 95
20 95
30 96
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FORMULATION  DEVELOPMENT  OF  MONTELUKAST  SODIUM  CHEWABLE
TABLETS 
Table No 14: Ingredients
S.NO                 INGREDIENTS 
1 MONTELUKAST SODIUM 
2 MANNITOL 
3 CELLOSE,MICROCRYSTALLINE 
4 HYDROXYPROPYL CELLOSE
5 CROSCARMELLOSE SODIUM
6 FERRIC OXIDE 
7 ASPARTAME 
8 ARTIFICAL CHERRY FLAVOUR 
9 MAGNESIUM  STERATE 
10 PURIFIED WATER
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Direct compression method
Table No 15:   Formula for F1 
S NO              INGREDIENTS            QUANTITY(mg)
1 Montelukast sodium 5.19
2 Mannitol 199.31
3 Cellulose,microcrystalline(PH102) 75.00
4 Croscarmellose sodium 9.00
5 Hydroxypropyl cellulose 6.00
6 Ferric oxide 0.60
7 Aspartame 1.50
8 Artificial cherry flavour 0.40
9 Magnesium sterate 3.00
Procedure 
1. Montelukast  Sodium,  Hydroxypropyl  cellulose  and  one  fourth  of  Cellulose,
Microcrystalline (PH 102) were sifted through # 40 mesh.
2. Red Ferric oxide was sifted through # 100 mesh and added to materials of step 1.
3. The materials of step 2 were re-sifted through #40 mesh.
4. Remaining Cellulose, Microcrystalline (PH 102) was sifted through #40 mesh and added
to materials of step 3.
5. The materials of step 4 were re-sifted through # 40 mesh.
6. Mannitol, Croscarmellose Sodium, Ferric oxide, Aspartame, Artificial cherry flavour was
sifted through # 40 mesh.
7. The materials of step 6 were re-sifted through # 40 mesh.
8. Magnesium stearate was sifted through # 60 mesh.
9. The above blend of step 7 was lubricated with Magnesium Stearate.
10. The lubricated blend was compressed into tablets.
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WET GRANULATION METHOD:
Table No 16: Formula for F2 to F8
S.NO INGREDIENTS F2(mg
)
F3(mg
)
F4(mg
)
F5(mg
)
F6(mg
)
F7(mg
)
F8(mg)
INTRAGRANULAR  EXCIPIENTS
1 Montelukast sodium 5.19 5.19 5.19 5.19 5.19 5.19 5.19
2 Mannitol 201.61 201.61 200.11 198.61 199.61 199.61 196.61
3 Cellulose
Microcrystalline 
59.00 57.50 57.50 59.50 57.00 55.50 59.00
4 Croscarmellose sodium 1.50 2.25 3.00 3.75 4.50 5.25 6.00
5 Ferric oxide 0.30 0.30 0.30 0.30 0.30 0.30 0.30
GRANULATING  FLUID 
6 Hydroxypropyl cellulose 6.00 6.00 6.00 6.00 6.00 6.00 6.00
7 Purified water Q.S Q.S .Q.S Q.S Q.S Q.S Q.S
EXTRAGRANULATING EXCIPIENTS 
8 Cellulose,microcrystalline 20.00 20.00 20.00 20.00 20.00 20.00 20.00
9 Croscarmellose sodium 1.50 2.25 3.00 3.75 4.50 5.25 6.00
10 Aspartame 1.50 1.50 1.50 1.50 1.50 1.50 1.50
11 Cherry flavour 0.40 0.40 0.40 0.40 0.40 0.40 0.40
12 Magnesium sterate 3.00 3.00 3.00 3.00 3.00 3.00 3.00
Total 300 300 300 300 300 300 300
Procedure:
1. Intragranular  materials  i.e.  Montelukast  Sodium,  40%  of  Mannitol  were  passed  through
#40mesh.
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2. Ferric oxide was passed through #80 mesh and was added to step 1.
3. The materials of step 2 were resifted through # 40 mesh.
4. Equal quantities of step 3 and remaining 60% mannitol were co-sifted through # 40 mesh.
5. Cellulose, Microcrystalline (PH 101) was sifted and resifted through # 40 mesh.
6. The above material was mixed with step 4 in rapid mixing granulator.
7. The binder solution was prepared by dispersing Hydroxypropyl cellulose in sufficient quantity
of purified water.
8. The dry mix of step-6 was granulated using binder solution of step-7 to get  wet  mass of
desired consistency.
9. The wet mass was dried in fluid bed dryer at 60ºC ± 5ºC.
10. Dried granules were milled in Co-mill using 1.13mm screen at medium fast speed.
11.  Extragranular excipients i.e. Cellulose, Microcrystalline, Croscarmellose Sodium were sifted
through #40mesh.
12. Artificial cherry flavour and Aspartame was passed  through # 60 mesh.
13. The above materials of step 11 & step 12 were blended with the dried granules of step 10.
14. Magnesium stearate was passed through #60mesh.
15. The above blend was lubricated with Magnesium stearate of step 14.
16. Then finally the lubricated blend was compressed into Tablets.
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                                        RESULTS AND DISCUSSION 
Table No 17:  DRUG–EXCIPIENTS COMPATIBILITY STUDIES
     67
S.NO          Ingredients    Rati
o 
                   Description
Initial 500C(3 weeks)
1 Montelukast Sodium     - Off  white  to  pale
yellow colour powder.
NCC
2 Montelukast  Sodium
+Mannitol
1:10 white colour powder NCC
3 Montelukast
sodium+cellulose
microcrystalline (PH 101)
1:10 White  to  off  white
colour powder 
NCC
4 Montelukast
sodium+cellulose
microcrystalline (PH 102)
1:5 White  to  off  white
colour powder
NCC
5 Montelukast
sodium+croscarmellulose
sodium 
1:2.5 White  to  off  white
colour powder
NCC
6 Montelukast
sodium+hydroxypropyl
cellulose 
1:3 Off  white  to  cream
colour powder 
NCC
7 Montelukast
sodium+aspartame 
1:1 White  to  off  white
colour powder
NCC
8 Montelukast  sodium+cherry
flavour 
1:1 Off  white  to  cream
colour powder
NCC
9 Montelukast  sodium+ferric
oxide 
1:1 light  pink  color
powder 
NCC
10 Montelukast  sodium  sodium
+ magnesium sterate 
1:1 White powder NCC
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                   Fig No 5:  FTIR Spectra of Montelukast sodium final formulation
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Discussion: 
The drug and excipient compatability studies were performed by means of physical mixture
of drug and excipients in different ratios (1:1,1:1,1:2.5,1:3,1:5,1:10) at 500C for one month
and no characteristic  change were  observed.  The compatability was  studied  with IR  and
peaks indicate that there is no interaction with excipients and so drug is compatable with the
formulation components.
Table No 18: Pre-compression parameters for formulation: 
Formula
Angle of repose
        (θ)
Bulk
density
(g/ml)
Tapped
density
(g/ml)
Compressibility
index (%)
Hausner’s
ratio
F1
42.8±0.03 0.466±0.04
0.626±0.01
25.55±0.51 1.34±0.98
F2 37.23±0.02 0.581±0.06 0.735±0.04 20.95±0.40 1.26±0.22
F3 32.21±0.01 0.588±0.05 0.757±0.02 22.32±0.36 1.28±0.12
F4 29.24±0.01 0.595±0.03 0.769±0.02 22.62±0.22 1.29±0.23
F5 24.70±0.03 0.602±0.04 0.781±0.08 22.91±0.21 1.29±15
F6 20.8±0.08 0.617±0.04 0.806±0.03 23.44±0.19 1.30±0.12
F7 22.71±0.01 0.641±0.04 0.833±0.02 23.04±0.17 1.29±0.29
F8 39.69±0.02 0.649±0.03 0.862±0.03 23.70±0.51 1.32±0.98
Mean±SD, (n=3)
Discussion: 
The blends was analysed for the parameters such as angle of repose, bulk density,  tapped
density,  compressibility  index,  hausner`s  ratio,  and  were  found  to  be  within  limits.  F1
formulation done by direct compression was found to be sticking to the punches of the tablet
press, so it was not taken further studies. So F2 TO F8 formulation wet granulation was taken
for further studies.
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Table No 19: Post compression parameters 
Formula Avg. weight(mg) Thickness(mm) Hardness(kg/cm2) Friability (%)
F2 301±0.12 4.31±0.0005 3.2±0.17 0.99
F3 297.0±0.23 4.29±0.0012 3.0±0.12 0.39
F4 297.4±0.12 4.28±0.0031 3.4±0.14 0.28
F5 298.0±0.01 4.25±0.0034 3.2±0.02 0.20
F6 301.5±0.25 4.26±0.0051 3.2±0.15 0.16
F7 302.2±0.14 4.25±0.0059 3.1±0.10 0.15
F8 301.4±0.28 4.28±0.0032 3.1±0.01 0.19
Mean±SD,(n=3)
Discussion: 
Tablets hardness of each formulation was analysed and found to be good in the range of 3 to
4.5 kg/cm2 . So they were taken for further studies.
Tablets thickness was almost uniform in all formulation and was found to be in the range of
4.25mm to 4.60mm.
The total weight of each formulation was not maintained constant, but the weight variation
was within limits of ±5%.
Friability were found to be less than 1% and considered to be satisfactory in the range of
0.15% to 0.99%.
Table no 20:     Post compression parameters
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Formula Disintegration time 
         (sec)
Water content 
       (w/w)
Assay(%)
F2 65±2 1.92±0.05 101.4±0.03
F3 62±3 1.90±0.09 98.7±0.01
F4 50±2 1.90±0.01 98.0±0.1
F5 42±4 1.84±0.17 100.5±0.18
F6 36±1 1.73±0.05 99.2±0.01
F7 38±3 1.71±0.5 99.3±0.03
F8 38±1 1.75±0.02 99.0±0.5
Mean±SD,(n=3)
Discussion:
The prepared tablets were checked for disintegration time, water content and assay and all the
tests formulations were passed. The assay ranges were found to be 99 to 102%.
The disintegration time was within 1-1.5 minutes.  The water content done by Karl  fisher
method was also within range of 1.70 to 1.95%w/w.
In Vitro Dissolution Study
  TABLE NO 21:Data for Standard Curve of Montelukast sodium 
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S. No. Conc. (µg/ml) Response
1 10 581819
2 20 1159645
3 30 1739469
4 40 2298302
5 50 2904228
                  Fig. No 6: HPLC Chromatogram for Montelukast sodium  in methanol
    
Table No 22:   In Vitro dissolution data by HPLC analysis for Montelukast sodium.
Peak Name Rt(min) Area (µV
2
sec)
Theoretical
plates
Tailing
Factor Resolution
Montelukast
sodium 5.501 581819 2640 1.3 -
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Table No 23: In Vitro release profiles study of different formulation:
Sampling
time
(minutes)
                                       Drug release profile (% drug release )
F2 F3 F4 F5 F6 F7 F8
10 80±0.90 82±0.52 82±0.43 85±0.24 88±0.23 86±0.28 86±0.90
15 84±0.82 88±0.85 86±0.56 89±0.51 91±0.29 90±0.35 89±0.82
20 93±0.28 91±0.68 90±0.76 92±0.73 96±0.40 92±0.73 90±0.54
30 95±0.58 93±0.72 95±0.23 94±0.04 98±0.20 96±0.26 93±0.29
         Fig No 7:  Comparative In Vitro drug release profile of Formulation F2 to F8
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Discussion:
In Vitro drug release profiles for all formulations were carried out by using purified water
with 0.5% SLS as dissolution medium for 30 minutes. From the results obtained it was 
observed that the formulation F6 with3% concentration of croscarmellose sodium 
(superdisintegrant) shows better release rate with 98% within 30 minutes. So, the formulation
F6 was found to give best release rate with 98% (Cumulative % drug release). So F6 
formulation was taken for stability studies.
     Fig No8:   In Vitro drug release profile of formulation F2 –F8 and innovator product.
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Stability data  
Table No24 :   Physical and chemical parameters of Montelukast sodium tablets (F6 ) after 1
month at 40ºC ± 2ºC/75 %RH ± 5 %RH(packing: blister pack)    
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Parameter Initial 1 month 
Description Pink  colour  round  shaped
tablets 
No change 
Avg. weight(mg) 301.0 301.2
Hardness(kg/cm2) 3.2 3.0
Thickness(mm) 4.26 4.29
Friability (%) 0.16 0.14
Water content(w/w) 1.73 1.63
Assay (%) 99.2 101.2
Table No 25:     Dissolution profile of Montelukast sodium tablets (F6 ) after 1 month at
40ºC ± 2ºC/75 %RH ± 5 %RH(packing: blister pack)    
  Time interval (min)
Drug release percentage   
Initial Final 
10 88 86±0.25
15 91 89±0.59
20 96 94±0.15
30 98 96±0.85
         
Table No 26:   Physical and chemical parameters of Montelukast sodium tablets (F6 ) after 1
month at 40ºC ± 2ºC/75 %RH ± 5 %RH(packing: HDME BOTTLE )    
Parameter Initial 1 month 
Description Pink  colour  round  shaped
tablets
No change
Avg. weight(mg) 301.0 301.2
Hardness(kg/cm2) 3.2 3.0
Thickness(mm) 4.26 4.29
Friability (%) 0.16 0.14
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Water content(w/w) 1.73 1.63
Assay (%) 99.2 101.2
Table No 27:     Dissolution profile of Montelukast sodium tablets (F6) after 1 month at 40ºC
± 2ºC/75 %RH ± 5 %RH(packing: HDME BOTTLE )    
  Time interval (min) Drug release percentage   
Initial Final 
10 88 86±0.84
15 91 88±0.51
20 96 93±0.63
30 98 96±0.19
Mean±SD, (n=3)
Discussion:
Form the above 1 month stability data there was no characteristic change in the formulation
F6.
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SUMMARY AND CONCLUSION
Montelukast sodium is a leukotriene receptor antagonist used in maintenance and treatment
of asthma.
Montelukast  sodium  chewable  tablets  300mg  were  formulated  by  using  different
concentration of superdisintegrant croscarmellose sodium in 1 to 4% concentration.
FT-IR study performed for the identification and compatibility study of drug and excipients
and found that  there was no characteristic change in the drug –excipients powder mixture.
Hence,  these excipients were selected for the formulation development.  The Powder and
blends were evaluated for tests such as bulk density, tapped density, compressibility index,
hausner’s ratio before being punched as tablets.
The development was started with direct compression method (F1). The blend was having
poor flow property and was found to be sticking to the die walls of the compression machine
resulting in weight variation of tablets. So it was not taken for further studies. 
Formulations  F2  to  F8  were  formulated  using  wet  granulation  technique  where
concentration of croscarmellose sodium (superdisintegrant) was gradually increased from
1% to 4%. In formulation F2 to F6 the drug release increased upto 98% at the end of 30
minutes and in the formulation F7 and F8 the drug release was decreased to 93% in 30
minutes. In limit concentration (1-3%) of croscarmellose sodium as superdisintegrant there
was an increase in the release of the drug for F2 to F6 and after a limit concentration (3.5-
4%) of superdisintegrant there was a decrease in drug release in F7 and F8.
The formulation F2 to F8 were compared with that of innovator for drug release and the
final formulation F6 showed In vitro drug release (98%) which was found to be matching to
that of innovator.
The optimized batch (F6) tablets were packed in HDPE container and Blister packs and are
further studied for stability at 400C ± 20C/ 75% RH ± 5%RH for a period of one month.
Tablets were evaluated for assay and In vitro dissolution, but there was no significant change
during the study period.
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                                            CONCLUSION
It  can be concluded that chewable tablets of Montelukast sodium can be prepared by wet
granulation method using croscarmellose sodium as superdisintegrant. Chewable tablets of
Montelukast sodium with 3% of croscarmellose sodium gave better drug release of 98% with
minimum disintegration time with pleasant taste .This will improve patient compliance and
increase in bioavailability.
SCOPE FOR FURTHER STUDIES:
• Long term stability studies can be performed to assure quality of Montelukast sodium
chewable tablets 5mg. 
• Clinical studies can be conducted for the approved batches.
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